Goldman Sachs just refreshed its conviction lists of global stocks — giving one 67% upside

Published Sun, May 5 20247:30 PM EDTUpdated Wed, May 15 202412:23 AM EDT

Amala Balakrishner @in/amala-balakrishner @_amalabk

Goldman Sachs just refreshed its lists of top global stock picks, adding some and removing others. The investment bank's "Conviction List - Directors' Cut" aims to offer investors a "curated and active" list of 15 to 25 buy-rated stocks. The stocks are selected by a subcommittee designated by the bank's Investment Review Committee for each region. "The subcommittee will collaborate with each sector analyst to identify top ideas that offer a combination of conviction, a differentiated view and high risk-adjusted returns," Goldman said. Here are three of the latest additions to Goldman's directors' cut lists — for Asia-Pacific and Europe — that were given more than 30% upside potential in the next 12 months. London Stock Exchange Goldman is bullish on Britain's London Stock Exchange (LSEG) and believes that it is at the "start of revenue acceleration." "LSEG's mid- to high-single-digit organic revenue growth targets are supported by increasing wallet share with existing clients, market share gains and adjacent market expansion," the investment bank's analyst Oliver Carruthers wrote in a May 2 note on the bank's Europe list. The LSEG has, for example, partnered with Microsoft to jointly develop products and services for data and analytics , among other things. Goldman has a target price of 11,850 British pence ($148.71) on the stock, giving it around 30.7% upside potential. Samsung Biologics Goldman likes South Korean biotechnology company Samsung Biologics, which it says is "set to capitalize on growing demand for biologics CDMOs [contract development manufacturing organization] via its build-out of world-leading capacity." Other merits of the company include its "competitive pricing strategy," Goldman analyst Ziyi Chen wrote in a May 2 note on the bank's Asia-Pacific list. "Samsung Bio continues to gain client recognition, now partnering with 15 of the top 20 global players and 90 CMO [contract manufacturing organization] projects accumulated," he added. Goldman has a target price of 1,078,000 Korean won ($789.9) on the stock, implying nearly 40% potential upside. Neste Also among Goldman's additions to its directors' cut list is Finnish oil refining company Neste . The investment bank has a target price of 37 euros ($39.72) on the stock, which represents an upside potential of about 67%. The stock is "extremely well positioned to benefit from several regulatory tailwinds driving biofuels demand and which should start impacting profitability this/next year," analyst Michele Della Vigna wrote. Drivers of those regulatory tailwinds include the EU's Renewable Energy Directive targets for renewable diesel by 2030 and upcoming revisions to the U.S.' Low Carbon Fuel Standard program, according to Goldman. Those factors are behind Vigna's "12% above-consensus" EBITDA (earnings before interest, taxes, depreciation and amortization) forecast for Neste in 2025. — CNBC's Michael Bloom contributed to this report.